<div id=toc></div>

# Table of Contents

- [q-bio.BM](#q-bio.BM) [Total: 3]
- [cs.LG](#cs.LG) [Total: 2]
- [cs.AI](#cs.AI) [Total: 2]


<div id='q-bio.BM'></div>

# q-bio.BM [[Back]](#toc)

### [1] [IntFold: A Controllable Foundation Model for General and Specialized Biomolecular Structure Prediction](https://arxiv.org/abs/2507.02025)
*The IntFold Team,Leon Qiao,Wayne Bai,He Yan,Gary Liu,Nova Xi,Xiang Zhang*

Main category: q-bio.BM

TL;DR: IntFold是一种可控的分子结构预测基础模型，其精度与AlphaFold3相当，并采用更优的注意力内核，还能预测变构状态、受限结构及结合亲和力。


<details>
  <summary>Details</summary>
Motivation: 开发一种高精度的、适应性强的分子结构预测模型，以应对多种生物分子结构的预测需求。

Method: 使用定制注意力内核和适配器（adapters），增加新型置信度头（confidence head）来评估对接质量。

Result: IntFold在预测精度上与AlphaFold3相当，并能灵活预测多种生物分子结构及特性。

Conclusion: IntFold为生物分子结构预测提供了更灵活和准确的解决方案，同时揭示了训练过程中的关键洞察。

Abstract: We introduce IntFold, a controllable foundation model for both general and
specialized biomolecular structure prediction. IntFold demonstrates predictive
accuracy comparable to the state-of-the-art AlphaFold3, while utilizing a
superior customized attention kernel. Beyond standard structure prediction,
IntFold can be adapted to predict allosteric states, constrained structures,
and binding affinity through the use of individual adapters. Furthermore, we
introduce a novel confidence head to estimate docking quality, offering a more
nuanced assessment for challenging targets such as antibody-antigen complexes.
Finally, we share insights gained during the training process of this
computationally intensive model.

</details>


### [2] [Downregulation of aquaporin 3 promotes hyperosmolarity-induced apoptosis of nucleus pulposus cells through PI3K/Akt/mTOR pathway suppression](https://arxiv.org/abs/2507.02231)
*Yuan Sang,Huiqing Zhao,Jiajun Wu,Ting Zhang,Wenbin Xu,Hui Yao,Kaihua Liu,Chang Liu,Junbin Zhang,Ping Li,Depeng Wu,Yichun Xu,Jianying Zhang,Gang Hou*

Main category: q-bio.BM

TL;DR: AQP3缺乏在高渗环境下通过抑制PI3K/AKT/mTOR信号通路促进NPC凋亡，是椎间盘退变的关键机制。恢复AQP3表达可减轻氧化损伤和凋亡，有望成为治疗靶点。


<details>
  <summary>Details</summary>
Motivation: 高渗透压是椎间盘退变中NPC凋亡的重要因素，但AQP3在高渗环境下调控凋亡的具体机制尚不明确。

Method: 研究通过AQP3基因过表达和药物抑制，分析其对PI3K/AKT/mTOR信号通路、线粒体功能和ROS积累的影响，并使用IVDD大鼠模型验证。

Result: AQP3下调抑制PI3K/AKT/mTOR通路，导致线粒体功能障碍和ROS积累，加剧NPC凋亡和椎间盘退变。AQP3过表达可逆转这一效应。

Conclusion: AQP3是椎间盘退变中的重要保护因子，靶向调节AQP3可能成为治疗策略。

Abstract: Hyperosmolarity is a key contributor to nucleus pulposus cell (NPC) apoptosis
during intervertebral disc degeneration (IVDD). Aquaporin 3 (AQP3), a membrane
channel protein, regulates cellular osmotic balance by transporting water and
osmolytes. Although AQP3 downregulation is associated with disc degeneration,
its role in apoptosis under hyperosmotic conditions remains unclear. Here, we
demonstrate that hyperosmolarity induces AQP3 depletion, suppresses the
PI3K/AKT/mTOR signaling pathway, and promotes mitochondrial dysfunction and ROS
accumulation in NPCs. Lentiviral overexpression of AQP3 restores this pathway,
attenuates oxidative damage, and reduces apoptosis, preserving disc structure
in IVDD rat models. In contrast, pharmacological inhibition of AQP3 exacerbates
ECM catabolism and NP tissue loss. Our findings reveal that AQP3 deficiency
under hyperosmolarity contributes to NPC apoptosis via suppression of
PI3K/AKT/mTOR signaling, potentially creating a pathological cycle of disc
degeneration. These results highlight AQP3 as a promising therapeutic target
for IVDD.

</details>


### [3] [HelixDesign-Antibody: A Scalable Production-Grade Platform for Antibody Design Built on HelixFold3](https://arxiv.org/abs/2507.02345)
*Jie Gao,Jing Hu,Shanzhuo Zhang,Kunrui Zhu,Sheng Qian,Yueyang Huang,Xiaonan Zhang,Xiaomin Fang*

Main category: q-bio.BM

TL;DR: 该论文介绍了一个基于HelixFold3的高通量抗体设计平台HelixDesign-Antibody，用于大规模生成抗体候选序列并评估其与抗原的相互作用。


<details>
  <summary>Details</summary>
Motivation: 传统的抗体发现方法耗时且资源密集，急需一种高效、高通量的解决方案来优化这一过程。

Method: 平台利用高精度结构预测模型HelixFold3，结合高性能计算支持，实现高通量筛选和大规模抗体序列生成。

Result: 验证实验证明该平台能生成多样化的高质量抗体，展示了探索更大序列空间可提高寻找到最佳结合体的可能性。

Conclusion: HelixDesign-Antibody为大规模抗体设计提供了无缝、易用的解决方案，并在PaddleHelix平台上开放使用。

Abstract: Antibody engineering is essential for developing therapeutics and advancing
biomedical research. Traditional discovery methods often rely on time-consuming
and resource-intensive experimental screening. To enhance and streamline this
process, we introduce a production-grade, high-throughput platform built on
HelixFold3, HelixDesign-Antibody, which utilizes the high-accuracy structure
prediction model, HelixFold3. The platform facilitates the large-scale
generation of antibody candidate sequences and evaluates their interaction with
antigens. Integrated high-performance computing (HPC) support enables
high-throughput screening, addressing challenges such as fragmented toolchains
and high computational demands. Validation on multiple antigens showcases the
platform's ability to generate diverse and high-quality antibodies, confirming
a scaling law where exploring larger sequence spaces increases the likelihood
of identifying optimal binders. This platform provides a seamless, accessible
solution for large-scale antibody design and is available via the antibody
design page of PaddleHelix platform.

</details>


<div id='cs.LG'></div>

# cs.LG [[Back]](#toc)

### [4] [Guided Generation for Developable Antibodies](https://arxiv.org/abs/2507.02670)
*Siqi Zhao,Joshua Moller,Porfi Quintero-Cadena,Lood van Niekerk*

Main category: cs.LG

TL;DR: 该论文提出了一种基于离散扩散模型的抗体序列优化框架，结合自然抗体库和临床抗体数据，旨在提高抗体的开发性能（developability）。通过引入SVDD模块，该模型在保持自然性的同时，显著提升了预测的开发性能得分。


<details>
  <summary>Details</summary>
Motivation: 当前抗体开发不仅需要高亲和力，还需具备良好的可制造性、稳定性和安全性。这些特性统称为开发性能（developability）。为了通过计算方法优化抗体序列以满足这些要求，研究人员提出了这一框架。

Method: 论文提出了一种引导式离散扩散模型，该模型基于自然的配对重链和轻链序列（来自OAS）和246种临床抗体的开发性能数据。模型整合了一个SVDD模块，在不影响自然性的前提下，引导生成更具生物物理可行性的抗体候选序列。

Result: 在无约束生成中，该模型能够复现自然抗体库和已批准治疗抗体的全局特征；在SVDD引导下，预测的开发性能得分显著高于无引导基线。结合高通量开发性能实验，该框架能够迭代设计同时满足结合和生物物理标准的抗体。

Conclusion: 该研究为抗体设计提供了一种迭代的、机器学习驱动的解决方案，能够同时优化抗体的结合性能和开发性能，具有重要的临床应用潜力。

Abstract: Therapeutic antibodies require not only high-affinity target engagement, but
also favorable manufacturability, stability, and safety profiles for clinical
effectiveness. These properties are collectively called `developability'. To
enable a computational framework for optimizing antibody sequences for
favorable developability, we introduce a guided discrete diffusion model
trained on natural paired heavy- and light-chain sequences from the Observed
Antibody Space (OAS) and quantitative developability measurements for 246
clinical-stage antibodies. To steer generation toward biophysically viable
candidates, we integrate a Soft Value-based Decoding in Diffusion (SVDD) Module
that biases sampling without compromising naturalness. In unconstrained
sampling, our model reproduces global features of both the natural repertoire
and approved therapeutics, and under SVDD guidance we achieve significant
enrichment in predicted developability scores over unguided baselines. When
combined with high-throughput developability assays, this framework enables an
iterative, ML-driven pipeline for designing antibodies that satisfy binding and
biophysical criteria in tandem.

</details>


### [5] [Hierarchical Multi-Label Contrastive Learning for Protein-Protein Interaction Prediction Across Organisms](https://arxiv.org/abs/2507.02724)
*Shiyi Liu,Buwen Liang,Yuetong Fang,Zixuan Jiang,Renjing Xu*

Main category: cs.LG

TL;DR: HIPPO是一个用于跨物种蛋白质-蛋白质相互作用预测的分层对比学习框架，通过多层级生物表征匹配和分层对比损失函数，实现了高效且鲁棒的预测性能。


<details>
  <summary>Details</summary>
Motivation: 解决现有方法在低数据场景和跨物种预测中的局限性，尤其是在实验数据有限的生物中。

Method: 采用分层对比学习框架，结合蛋白质序列和层级属性，通过数据驱动的惩罚机制整合领域知识。

Result: 在基准数据集上表现优异，具有零样本迁移能力，适用于数据稀疏或分布不均的场景。

Conclusion: HIPPO为跨物种PPI预测提供了统一框架，并揭示了分层特征融合对捕捉保守相互作用决定因素的重要性。

Abstract: Recent advances in AI for science have highlighted the power of contrastive
learning in bridging heterogeneous biological data modalities. Building on this
paradigm, we propose HIPPO (HIerarchical Protein-Protein interaction prediction
across Organisms), a hierarchical contrastive framework for protein-protein
interaction(PPI) prediction, where protein sequences and their hierarchical
attributes are aligned through multi-tiered biological representation matching.
The proposed approach incorporates hierarchical contrastive loss functions that
emulate the structured relationship among functional classes of proteins. The
framework adaptively incorporates domain and family knowledge through a
data-driven penalty mechanism, enforcing consistency between the learned
embedding space and the intrinsic hierarchy of protein functions. Experiments
on benchmark datasets demonstrate that HIPPO achieves state-of-the-art
performance, outperforming existing methods and showing robustness in low-data
regimes. Notably, the model demonstrates strong zero-shot transferability to
other species without retraining, enabling reliable PPI prediction and
functional inference even in less characterized or rare organisms where
experimental data are limited. Further analysis reveals that hierarchical
feature fusion is critical for capturing conserved interaction determinants,
such as binding motifs and functional annotations. This work advances
cross-species PPI prediction and provides a unified framework for interaction
prediction in scenarios with sparse or imbalanced multi-species data.

</details>


<div id='cs.AI'></div>

# cs.AI [[Back]](#toc)

### [6] [STELLA: Self-Evolving LLM Agent for Biomedical Research](https://arxiv.org/abs/2507.02004)
*Ruofan Jin,Zaixi Zhang,Mengdi Wang,Le Cong*

Main category: cs.AI

TL;DR: STELLA是一种自我演化的AI代理，通过动态扩展的工具和推理策略库自动提升能力，解决了生物医学研究中AI代理静态工具集的局限性，并在多个基准测试中表现出色。


<details>
  <summary>Details</summary>
Motivation: 生物医学数据的快速增长和研究环境碎片化超出人类专家能力，现有AI代理因依赖静态工具集无法适应，需开发自适应系统。

Method: STELLA采用多代理架构，包含动态演化的推理策略模板库和自动发现整合新工具的工具海洋。

Result: STELLA在多个生物医学基准测试中表现最优，准确率显著提升（如Humanity's Last Exam达到26%），且随经验累积性能持续提高。

Conclusion: STELLA标志着AI代理系统朝动态学习和扩展能力迈出重要一步，加速生物医学发现。

Abstract: The rapid growth of biomedical data, tools, and literature has created a
fragmented research landscape that outpaces human expertise. While AI agents
offer a solution, they typically rely on static, manually curated toolsets,
limiting their ability to adapt and scale. Here, we introduce STELLA, a
self-evolving AI agent designed to overcome these limitations. STELLA employs a
multi-agent architecture that autonomously improves its own capabilities
through two core mechanisms: an evolving Template Library for reasoning
strategies and a dynamic Tool Ocean that expands as a Tool Creation Agent
automatically discovers and integrates new bioinformatics tools. This allows
STELLA to learn from experience. We demonstrate that STELLA achieves
state-of-the-art accuracy on a suite of biomedical benchmarks, scoring
approximately 26\% on Humanity's Last Exam: Biomedicine, 54\% on LAB-Bench:
DBQA, and 63\% on LAB-Bench: LitQA, outperforming leading models by up to 6
percentage points. More importantly, we show that its performance
systematically improves with experience; for instance, its accuracy on the
Humanity's Last Exam benchmark almost doubles with increased trials. STELLA
represents a significant advance towards AI Agent systems that can learn and
grow, dynamically scaling their expertise to accelerate the pace of biomedical
discovery.

</details>


### [7] [An AI-native experimental laboratory for autonomous biomolecular engineering](https://arxiv.org/abs/2507.02379)
*Mingyu Wu,Zhaoguo Wang,Jiabin Wang,Zhiyuan Dong,Jingkai Yang,Qingting Li,Tianyu Huang,Lei Zhao,Mingqiang Li,Fei Wang,Chunhai Fan,Haibo Chen*

Main category: cs.AI

TL;DR: AI驱动的自主实验室，支持复杂实验和多人使用，实现高效生物分子工程。


<details>
  <summary>Details</summary>
Motivation: 实现无需人工干预的自主科学研究，突破专家依赖和资源限制。

Method: 基于AI与实验设备的协同设计，开发多用户自动化实验室平台。

Result: 能够自主优化实验性能，达到专家水平，提高仪器利用率和实验效率。

Conclusion: 该平台为大规模‘科学即服务’提供了蓝图，推动生物材料研究。

Abstract: Autonomous scientific research, capable of independently conducting complex
experiments and serving non-specialists, represents a long-held aspiration.
Achieving it requires a fundamental paradigm shift driven by artificial
intelligence (AI). While autonomous experimental systems are emerging, they
remain confined to areas featuring singular objectives and well-defined, simple
experimental workflows, such as chemical synthesis and catalysis. We present an
AI-native autonomous laboratory, targeting highly complex scientific
experiments for applications like autonomous biomolecular engineering. This
system autonomously manages instrumentation, formulates experiment-specific
procedures and optimization heuristics, and concurrently serves multiple user
requests. Founded on a co-design philosophy of models, experiments, and
instruments, the platform supports the co-evolution of AI models and the
automation system. This establishes an end-to-end, multi-user autonomous
laboratory that handles complex, multi-objective experiments across diverse
instrumentation. Our autonomous laboratory supports fundamental nucleic acid
functions-including synthesis, transcription, amplification, and sequencing. It
also enables applications in fields such as disease diagnostics, drug
development, and information storage. Without human intervention, it
autonomously optimizes experimental performance to match state-of-the-art
results achieved by human scientists. In multi-user scenarios, the platform
significantly improves instrument utilization and experimental efficiency. This
platform paves the way for advanced biomaterials research to overcome
dependencies on experts and resource barriers, establishing a blueprint for
science-as-a-service at scale.

</details>
